The EPIDEMIOLOGICAL ANALYSIS OF ALCOHOLIC LIVER DISEASE IN BRAZIL BETWEEN THE YEARS OF 2017 AND 2022

• Autor(a) principal: Silva Gradil Costa, Larissa
• Data de Publicação: 2024
• Outros Autores: Sousa , Alexandre Magno de, Araújo, Bárbara Lettyccya Pereira Chacon de, Fonseca , Vitória Caroline Ramos, Barros, Bruna Carvalho de, Lima , Carlos Alexandre Neves, Recco , Giuliana Chaves, Guedes , Quezia Valeria da Costa, Carneiro, Raíssa Beatriz Silvestre, Silvestre , Maria Eduarda dos Santos, Zanoni, Rodrigo Daniel, Silva , Maria Fernanda Teixeira Souza
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/1128
• topic: Doença Hepática Alcoólica; Consumo de Bebida Alcoólica; Epidemiologia; Alcoholic Liver Disease; Alcoholic Drink Consumption; Epidemiology

Among the health problems resulting from the chronic use of alcohol, Alcoholic Liver Disease (ALD) appears as a consequence of the biochemical attacks caused by ethanol. This condition manifests itself through a spectrum of liver sequelae, which include steatosis, progressive fibrosis, alcoholic hepatitis and cirrhosis. This study aims to describe the prevalence of hospitalizations for alcoholic liver disease in Brazil, from 2018 to 2022. This is a descriptive, ecological and quantitative study that addresses hospital admissions for alcoholic liver disease from 2018 to 2022, based on secondary data from the Information Technology Department of the Unified Health System, following the variables: hospitalizations, deaths, sex, age group, average length of stay and hospital costs. 75,932 hospitalizations for ALD were recorded in Brazil, with a higher prevalence in the Southeast (43.07%). In every year, the number of hospitalizations among men is significantly higher than among women, with an average of 10,579 cases. The age group from 50 to 59 years old presented prevalence, corresponding to 31.31%. The Northeast had higher average length of stay and death, with a total of 9.3 days and 23.26%, respectively. It is crucial to implement strategies that improve early screening of patients with ALD, preventing disease progression and reducing morbidity and mortality.